LuminX is a startup company established in 2020. It provides preclinical one-stop solutions for therapeutic cells. While tracking cells in vivo through traditional methods such as PCR or imaging only provide very limited information. Those products lack accurate and rapid pre-clinical cell pharmacokinetic verification. Therefore, when cells are used as drugs in organisms, how to monitor cell positioning, quantification effectively, and validation analysis are significant challenges. The CEO of LuminX, Dr. Harry Su, applied the Nano-diamond technology developed from Academia Sinica and National Taiwan University into a one-stop cell pharmacokinetic testing platform, providing cell GPS positioning in vivo after cells are injected into the organism. It has six significant advantages:

1. Can be used in large animal models (pigs)
2. PK/PD of transplanted-cells
3. Background-free imaging
4. Single-cell detection sensitivity
5. High throughput quantification
6. No interference with cell potency